Latest PEGylation Stories
ANAHEIM, Calif., Jan. 2, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it has signed a definitive agreement to acquire all issued and outstanding shares of BioVectra Inc., for an upfront payment of C$50 million. BioVectra is a supplier of contract manufacturing services to the global pharmaceutical and biotechnology industry and manufactures active pharmaceutical ingredients (API's), chemical intermediates, and bioprocessing reagents....
Intellitech's new micro pump promotes the rapid growth for emerging bio tech. The i-FILL® Micro’s disposable fluid path and unmatched dispense accuracy combine to save time and money by eliminating cleaning protocols and reducing product waste. Westminster, MD (PRWEB) December 18, 2012 Intellitech, leading provider of liquid filling equipment for biotech (ELISA kit, reagent, cell therapy, biologics) and pharmaceutical is delivering unmatched performance with the i-FILL®...
SEATTLE, Dec. 10, 2012 /PRNewswire/ -- Aequus BioPharma, a majority owned subsidiary of Cell Therapeutics, Inc., announced today that Ronald J. Berenson, M.D. was appointed President and CEO of Aequus. In his new position, Dr. Berenson will expand business and product development opportunities for Aequus' GlycoPolymer technology. Aequus is currently developing its GlycoPolymer technology aimed at creating novel biopharmaceuticals with improved pharmacokinetic properties that...
BRIDGEWATER, N.J., Dec. 5, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Robert (Bob) G. Savage has been elected to the Company's Board of Directors, effective December 5, 2012. "Bob is a proven leader with an exceptional track record of success, and we are fortunate to have a pharmaceutical executive with such a wealth of experience join our Board of Directors," stated Stephen O. Jaeger, Chairman of Savient's Board of Directors. Mr. Savage...
DUBLIN, Dec. 3, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled and dosed in a clinical trial of Erwinaze(®) (asparaginase Erwinia chrysanthemi) administered intravenously (IV) as an alternative method of administration to treat patients with acute lymphoblastic leukemia (ALL) with hypersensitivity to E. coli-derived asparaginase therapy. "Intravenous administration of Erwinaze may provide meaningful benefit to...
NES-ZIONA, Israel, Nov. 13, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that the U.S. Patent and Trademark Office issued a notice of allowance for a patent application covering the company's long-acting reversible-pegylation technology (RPeg). Upon issuance, the new patent will provide added intellectual property protection, including additional compositions and configurations of long-acting drug product, in addition to the already-issued U.S. patent...
BRIDGEWATER, N.J., Nov. 12, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that new data from an open-label extension (OLE) study published in the Annals of the Rheumatic Diseases reinforced the safety and efficacy profile of KRYSTEXXA(®) (pegloticase) treatment for refractory chronic gout (RCG) over the long-term. OLE data aligned with outcomes seen in the KRYSTEXXA pivotal Phase III clinical trials, with no new safety signals identified....
SAN FRANCISCO, Nov. 12, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will host a conference call with investors to discuss the positive Phase 3 clinical results announced by its partner AstraZeneca. Howard Robin, president and chief executive officer, will host the conference call, which will begin at 8:15 a.m. Eastern Standard Time (EST)/5:15 a.m. Pacific Standard Time (PST). A live audio-only Webcast of this conference call can be accessed through a link that is...
BOSTON, Nov. 10, 2012 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (Janssen) today announced that the use of one once-daily pill of the investigational protease inhibitor simeprevir (TMC435) administered with pegylated interferon and ribavirin led to higher rates of sustained viral response at 24 weeks (SVR24) compared to placebo in patients with Metavir scores of F3 and F4 who were treatment naive and treatment experienced with genotype 1 hepatitis C. Simeprevir was also generally...
SAN FRANCISCO, Nov. 6, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2012 on Tuesday, November 13, 2012, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). The press release and a live audio-only Webcast of the conference call...
